{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-278606","form_type":"8-K","ticker":"VTRS","cik":"0001792044","company_name":"Viatris Inc","filed_at":"2022-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.136380+00:00","generated_at":"2026-06-22T05:43:44.226521+00:00","sec_items":["7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Viatris acquires Oyster Point Pharma and Famy Life Sciences for $700-750M to create ophthalmology franchise","bullets":["Aggregate purchase price $700-750M cash; Oyster Point at $11/share upfront plus up to $2 CVR; expects Q1 2023 close.","Sees combined ops adding at least $1B net sales and $500M adj. EBITDA by 2028; expects acquisitions to be adjusted EPS accretive in 2023.","Reaffirms total pre-tax proceeds from Biocon Biologics and non-core asset divestitures up to ~$9B; plans $1B stock repurchase program in 2023.","Provides 2024-2028 financial targets: total revenue CAGR ~3%, adj. EBITDA CAGR ~4-5%, adj. EPS CAGR ~mid-teens.","Ophthalmology division to be led by current Oyster Point CEO Jeff Nau upon closing."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-278606","json":"https://secwatch.observer/filing/0001193125-22-278606.json","markdown":"https://secwatch.observer/filing/0001193125-22-278606.md","text":"https://secwatch.observer/filing/0001193125-22-278606.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1792044/000119312522278606/0001193125-22-278606-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1792044/000119312522278606/d496725d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T05:43:44.226521+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}